AUTH/3667/6/22 - Health professional v Roche

Certification of the mobile version of a webpage and alleged off-licence promotion

  • Received
    26 June 2022
  • Case number
  • Applicable Code year
  • Completed
    14 June 2023
  • No breach Clause(s)
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to the mobile version of a webpage on the Roche resources website, within the congress and meetings section, which allegedly required separate certification and allegedly promoted Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab) outside of their marketing authorisations.

The Panel ruled no breach of the following Clauses of the 2021 Code as it did not consider that the complainant had established that the difference in final form between the desktop and mobile versions meant that the two versions should have been certified separately nor did it consider that, within the context of the webpage, the title of a video, ‘Tailoring Treatment for Patients with HER-2 positive Early Breast Cancer’, which was a virtual meeting, implied that Kadcyla and Perjeta were licensed for use in all patients with HER-2 positive early breast cancer as alleged.

No Breach of Clause 2

Requirement that material must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards

No Breach of Clause 8.1

Requirement to certify promotional material

No Breach of Clause 11.2

Requirement not to promote a medicine for an unlicensed indication

This summary is not intended to be read in isolation.
For full details, please see the full case report below.